$EXEL
EXELIXIS, INC.

2023 Q2 Form 10-Q Financial Statement

#000093976723000048 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $469.8M $408.8M
YoY Change 31.99% 14.83%
Cost Of Revenue $17.71M $14.32M
YoY Change 34.1% 8.42%
Gross Profit $452.1M $394.5M
YoY Change 31.91% 15.08%
Gross Profit Margin 96.23% 96.5%
Selling, General & Admin $141.7M $131.4M
YoY Change 37.78% 27.74%
% of Gross Profit 31.34% 33.31%
Research & Development $232.6M $234.2M
YoY Change 48.44% 49.51%
% of Gross Profit 51.44% 59.38%
Depreciation & Amortization $6.040M $6.855M
YoY Change 34.52% 52.67%
% of Gross Profit 1.34% 1.74%
Operating Expenses $374.3M $365.6M
YoY Change 44.22% 40.88%
Operating Profit $77.85M $28.83M
YoY Change -6.48% -65.37%
Interest Expense $22.54M $19.50M
YoY Change 373.85% 970.36%
% of Operating Profit 28.95% 67.64%
Other Income/Expense, Net -$5.000K -$54.00K
YoY Change -103.05% -132.93%
Pretax Income $100.4M $48.28M
YoY Change 13.42% -43.35%
Income Tax $19.21M $8.250M
% Of Pretax Income 19.13% 17.09%
Net Earnings $81.18M $40.03M
YoY Change 18.38% -41.63%
Net Earnings / Revenue 17.28% 9.79%
Basic Earnings Per Share $0.25 $0.12
Diluted Earnings Per Share $0.25 $0.12
COMMON SHARES
Basic Shares Outstanding 325.6M shares 324.1M shares
Diluted Shares Outstanding 327.3M shares 326.3M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.267B $1.313B
YoY Change -17.47% -16.38%
Cash & Equivalents $464.5M $540.6M
Short-Term Investments $802.3M $772.5M
Other Short-Term Assets $62.26M $60.65M
YoY Change 28.95% 13.73%
Inventory $28.64M $29.91M
Prepaid Expenses
Receivables $232.8M $233.9M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.591B $1.638B
YoY Change -13.69% -11.13%
LONG-TERM ASSETS
Property, Plant & Equipment $115.0M $116.2M
YoY Change 8.32% 9.46%
Goodwill $63.68M $63.68M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $838.6M $805.1M
YoY Change 80.78% 99.03%
Other Assets $533.4M $519.3M
YoY Change 283.77% 122.17%
Total Long-Term Assets $1.552B $1.506B
YoY Change 91.27% 85.58%
TOTAL ASSETS
Total Short-Term Assets $1.591B $1.638B
Total Long-Term Assets $1.552B $1.506B
Total Assets $3.142B $3.143B
YoY Change 18.4% 18.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.99M $32.62M
YoY Change 50.38% 88.72%
Accrued Expenses $150.4M $139.1M
YoY Change -10.55% -12.05%
Deferred Revenue $6.801M $7.064M
YoY Change -7.46%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $339.6M $327.6M
YoY Change 17.48% 13.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $274.9M $67.38M
YoY Change 2096.32% -5.35%
Total Long-Term Liabilities $274.9M $67.38M
YoY Change 2096.32% -5.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $339.6M $327.6M
Total Long-Term Liabilities $274.9M $67.38M
Total Liabilities $614.5M $588.2M
YoY Change 70.58% 63.27%
SHAREHOLDERS EQUITY
Retained Earnings $11.19M $5.803M
YoY Change -107.56%
Common Stock $320.0K $325.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.528B $2.555B
YoY Change
Total Liabilities & Shareholders Equity $3.142B $3.143B
YoY Change 18.4% 18.43%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $81.18M $40.03M
YoY Change 18.38% -41.63%
Depreciation, Depletion And Amortization $6.040M $6.855M
YoY Change 34.52% 52.67%
Cash From Operating Activities $121.0M $84.41M
YoY Change -18.1% -42.86%
INVESTING ACTIVITIES
Capital Expenditures $5.937M $12.02M
YoY Change 5.85% -314.37%
Acquisitions
YoY Change
Other Investing Activities -$67.85M -$37.57M
YoY Change -44.75% -45.5%
Cash From Investing Activities -$73.79M -$49.59M
YoY Change -1.01% -33.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -124.8M $4.586M
YoY Change -60974.15% 2137.07%
NET CHANGE
Cash From Operating Activities 121.0M $84.41M
Cash From Investing Activities -73.79M -$49.59M
Cash From Financing Activities -124.8M $4.586M
Net Change In Cash -77.60M $39.40M
YoY Change -205.74% -46.31%
FREE CASH FLOW
Cash From Operating Activities $121.0M $84.41M
Capital Expenditures $5.937M $12.02M
Free Cash Flow $115.0M $72.38M
YoY Change -19.05% -52.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000939767
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-30235
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
EXELIXIS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3257395
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1851 Harbor Bay Parkway
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Alameda,
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94502
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
837-7000
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock $.001 Par Value per Share
CY2023Q1 dei Trading Symbol
TradingSymbol
EXEL
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
325636738 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
540597000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
501195000 usd
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
772536000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
807273000 usd
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
233923000 usd
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
214784000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
29908000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
33299000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
60654000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
62211000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1637618000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1618762000 usd
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
806615000 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
756731000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
116212000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110624000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
229603000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
231110000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
63684000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
63684000 usd
CY2023Q1 exel Operating Lease Right Of Use Asset And Other Assets
OperatingLeaseRightOfUseAssetAndOtherAssets
289627000 usd
CY2022Q4 exel Operating Lease Right Of Use Asset And Other Assets
OperatingLeaseRightOfUseAssetAndOtherAssets
290578000 usd
CY2023Q1 us-gaap Assets
Assets
3143359000 usd
CY2022Q4 us-gaap Assets
Assets
3071489000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
32621000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
32667000 usd
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
56551000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
77158000 usd
CY2023Q1 exel Accrued Clinical Liabilities Current
AccruedClinicalLiabilitiesCurrent
64210000 usd
CY2022Q4 exel Accrued Clinical Liabilities Current
AccruedClinicalLiabilitiesCurrent
65072000 usd
CY2023Q1 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
66405000 usd
CY2022Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
50350000 usd
CY2023Q1 exel Accrued Collaboration Liability Current
AccruedCollaborationLiabilityCurrent
18324000 usd
CY2022Q4 exel Accrued Collaboration Liability Current
AccruedCollaborationLiabilityCurrent
20188000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
89486000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
78924000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
327597000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
324359000 usd
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6299000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6582000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
186948000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
190170000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
67379000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
61951000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
588223000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
583062000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
324985000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
324985000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
323951000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
323951000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
325000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
324000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2558297000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2536849000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9289000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14521000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
5803000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34225000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2555136000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2488427000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3143359000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3071489000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
408788000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
355980000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14315000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13203000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
234246000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
156671000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
131397000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
102863000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
379958000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
272737000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
28830000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
83243000 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
19502000 usd
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
1822000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-54000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
164000 usd
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
48278000 usd
CY2022Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
85229000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8250000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16656000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
40028000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
324420000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
319582000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
326279000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
323289000 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
40028000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-1507000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1656000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5232000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5907000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
45260000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
62666000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2488427000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
40028000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5232000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7080000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2523000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16892000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2555136000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2210615000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5907000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5513000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4960000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20017000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2293851000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
40028000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6855000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4490000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
16661000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
19759000 usd
CY2023Q1 exel Noncash Lease Expense
NoncashLeaseExpense
6731000 usd
CY2022Q2 exel Noncash Lease Expense
NoncashLeaseExpense
1385000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 usd
CY2022Q2 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-15318000 usd
CY2023Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
36500000 usd
CY2022Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3743000 usd
CY2022Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1580000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
19178000 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-91793000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8370000 usd
CY2022Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3520000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10372000 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3605000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-707000 usd
CY2022Q2 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1169000 usd
CY2023Q1 exel Increase Decrease In Accrued Collaboration Liabilities
IncreaseDecreaseInAccruedCollaborationLiabilities
-1864000 usd
CY2022Q2 exel Increase Decrease In Accrued Collaboration Liabilities
IncreaseDecreaseInAccruedCollaborationLiabilities
-54261000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1123000 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7376000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
84408000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
147719000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12024000 usd
CY2022Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5609000 usd
CY2023Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
36500000 usd
CY2022Q2 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 usd
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
311837000 usd
CY2022Q2 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
336545000 usd
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
310769000 usd
CY2022Q2 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
267615000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49592000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74539000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7143000 usd
CY2022Q2 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4891000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2557000 usd
CY2022Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4686000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4586000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
205000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
39402000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
73385000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
502677000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
663891000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
542079000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
737276000 usd
CY2023Q1 exel Number Of Countries With Drug Approval Excluding The Us
NumberOfCountriesWithDrugApprovalExcludingTheUS
67 country
CY2023Q1 us-gaap Fiscal Period
FiscalPeriod
<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2023, which is a 52-week fiscal year, will end on December 29, 2023 and fiscal year 2022, which was a 52-week fiscal year, ended on December 30, 2022. For convenience, references in this report as of and for the fiscal period ended April 1, 2022, and as of and for the fiscal years ending December 29, 2023 and ended December 30, 2022 are indicated as being as of and for the period ended March 31, 2022, and the years ending December 31, 2023 and ended December 31, 2022, respectively.
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
408788000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
355980000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
408788000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
355980000 usd
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
77231000 usd
CY2023Q1 exel Valuation Allowances And Reserves Additions For Sales In Current Period
ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
158985000 usd
CY2023Q1 exel Valuation Allowances And Reserves Additions For Sales In Prior Period
ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
-1063000 usd
CY2023Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
147598000 usd
CY2023Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
87555000 usd
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1387000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1659000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7064000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7488000 usd
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6299000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6582000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13363000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14070000 usd
CY2023Q1 exel Contract With Customer Liability Including New Contract Revenue Recognized
ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
2000000 usd
CY2022Q2 exel Contract With Customer Liability Including New Contract Revenue Recognized
ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
2400000 usd
CY2023Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
37900000 usd
CY2022Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
31700000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
69000000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
540597000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
501195000 usd
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1482000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1482000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
542079000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
502677000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1886976000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2571000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14277000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1875270000 usd
CY2023Q1 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
2132936000 usd
CY2023Q1 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2571000 usd
CY2023Q1 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14277000 usd
CY2023Q1 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
2121230000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1887060000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
589000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
19034000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1868615000 usd
CY2022Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
2085126000 usd
CY2022Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
589000 usd
CY2022Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
19034000 usd
CY2022Q4 exel Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
2066681000 usd
CY2023Q1 us-gaap Interest Receivable
InterestReceivable
10100000 usd
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
7300000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
845425000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
14277000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1030810000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
19034000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
237 investment
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
285 investment
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
317100000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
6300000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
237600000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
6100000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1071653000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1114884000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
803617000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
753731000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1875270000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1868615000 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
8777000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
8077000 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
53610000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
43564000 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8490000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10635000 usd
CY2023Q1 us-gaap Inventory Gross
InventoryGross
70877000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
62276000 usd
CY2023Q1 us-gaap Inventory Gross
InventoryGross
70877000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
62276000 usd
CY2023Q1 exel Share Based Compensation Arrangement By Share Based Payment Award Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
1 shares
CY2023Q1 exel Share Based Compensation Arrangement By Share Based Payment Award Reduction In Share Reserve Due To Other Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
2 shares
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16661000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19759000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16661000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19759000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9738700 shares
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
14000000 usd
CY2023Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
550000000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.171
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.195
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
40028000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
68573000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
324420000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
319582000 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1859000 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3707000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
326279000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
323289000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2021Q2 exel Loss Contingency Number Of Lawsuits Consolidated
LossContingencyNumberOfLawsuitsConsolidated
2 segment

Files In Submission

Name View Source Status
exel-20230331_htm.xml Edgar Link completed
exel-20230331_def.xml Edgar Link unprocessable
0000939767-23-000048-index-headers.html Edgar Link pending
0000939767-23-000048-index.html Edgar Link pending
0000939767-23-000048.txt Edgar Link pending
0000939767-23-000048-xbrl.zip Edgar Link pending
exel-20230331.htm Edgar Link pending
exel-20230331.xsd Edgar Link pending
exel-20230331_g1.jpg Edgar Link pending
exel20230331exhibit31110q.htm Edgar Link pending
exel20230331exhibit31210q.htm Edgar Link pending
exel20230331exhibit32110q.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
exel-20230331_cal.xml Edgar Link unprocessable
exel-20230331_pre.xml Edgar Link unprocessable
exel-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending